NCT02492204

Brief Summary

The main objective is the study of the role of IL33/ST2 axis in the pathogenesis of ARDS, it´s value as prognosis marker and as therapeutic target.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
200

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jul 2015

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 1, 2015

Completed
Same day until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2015

Completed
2 days until next milestone

First Submitted

Initial submission to the registry

July 3, 2015

Completed
5 days until next milestone

First Posted

Study publicly available on registry

July 8, 2015

Completed
4.4 years until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2019

Completed
Last Updated

February 26, 2019

Status Verified

January 1, 2018

Enrollment Period

Same day

First QC Date

July 3, 2015

Last Update Submit

February 24, 2019

Conditions

Acute Respiratory Distress Syndrome

Outcome Measures

Primary Outcomes (1)

  • Prognostic value of the IL-33/ST2 axis in patients with ARDS.

    60 days

Secondary Outcomes (1)

  • Value of IL33/ST2 axis to predict development of ARDS in risk patients

    60 days

Study Arms (2)

Survivors

Non survivors

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients with ARDS criteria according to Berlin definition or risk pathologies

You may qualify if:

  • ARDS
  • Risk pathologies to develop ARDS (sepsis, pancreatitis, pneumonia, massive transfussion, politraumatics)

You may not qualify if:

  • Age under 18
  • Pregnancy
  • Undergoing a clinical trial

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Hospital Universitary Vall d´Hebron

Barcelona, 08035, Spain

Location

MeSH Terms

Conditions

Respiratory Distress Syndrome

Condition Hierarchy (Ancestors)

Lung DiseasesRespiratory Tract DiseasesRespiration Disorders

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Target Duration
60 Days
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 3, 2015

First Posted

July 8, 2015

Study Start

July 1, 2015

Primary Completion

July 1, 2015

Study Completion

December 1, 2019

Last Updated

February 26, 2019

Record last verified: 2018-01

Locations

ES(1)